Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (541-550 of 649) with videos related to

Pageof 65
Sort By:
Breast Cancer Research and Treatment|October 19, 2013
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutationAdriana Valentini, Jan Lubinski, Tomasz Byrski, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
NPJ Breast Cancer|June 25, 2026
Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriersMartin Widschwendter, Rita Schmutzler, Nora Pashayan, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerA Gennari, F André, C H Barrios, et al.
JAMA Oncology|February 29, 2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJan Lubinski, Joanne Kotsopoulos, Pal Moller, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Pageof 65

Showing results (541-550 of 649) with videos related to

Sort By:
Pageof 65
Breast Cancer Research and Treatment|October 19, 2013
The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutationAdriana Valentini, Jan Lubinski, Tomasz Byrski, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
NPJ Breast Cancer|June 25, 2026
Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriersMartin Widschwendter, Rita Schmutzler, Nora Pashayan, et al.
JAMA|September 3, 2010
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortalitySusan M Domchek, Tara M Friebel, Christian F Singer, et al.
Breast Cancer Research and Treatment|August 21, 2013
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerAllan Lipton, Laurie Goodman, Kim Leitzel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerA Gennari, F André, C H Barrios, et al.
JAMA Oncology|February 29, 2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJan Lubinski, Joanne Kotsopoulos, Pal Moller, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
Pageof 65